HIC
NVO

Hamrick Investment Counsel’s Novo Nordisk NVO Stock Holding History

Hamrick Investment Counsel’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4K Sell
50
-40
-44% -$1.72K ﹤0.01% 169
2026
Q1 		$3.42K Buy
90
+40
+80% +$1.9K ﹤0.01% 294
2025
Q4 		$2.54K Buy
+50
New +$2.56K ﹤0.01% 168

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Hamrick Investment Counsel's NVO Position: Q2 2026 in Review

Hamrick Investment Counsel reduced its Novo Nordisk (NVO) stake by 44% in Q2 2026, selling an estimated $1.72K and leaving 50 shares worth $2.4K. The position accounts for ﹤0.01% of the portfolio, ranked #169.

Hamrick Investment Counsel first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.42K in Q1 2026. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Hamrick Investment Counsel held 50 shares of Novo Nordisk worth $2.4K as of Q2 2026.
  • Hamrick Investment Counsel sold 40 Novo Nordisk shares in Q2 2026, an estimated $1.72K.
  • Novo Nordisk made up ﹤0.01% of Hamrick Investment Counsel's portfolio in Q2 2026, its #169 holding.
  • Hamrick Investment Counsel first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Hamrick Investment Counsel's Novo Nordisk position peaked at $3.42K in Q1 2026.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Hamrick Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.